Dr. Sudhir Srivastava performed the first intercontinental robotic cardiac telesurgery using SSi Mantra 3, successfully connecting France and India.
Quiver AI Summary
SS Innovations International, Inc. announced a historic achievement in the field of robotic surgery, as Dr. Sudhir Srivastava successfully executed the world’s first intercontinental robotic cardiac telesurgery on July 19, 2025. Utilizing the SSi Mantra 3 surgical robotic system, the procedure was performed remotely from Strasbourg, France, over 4,000 miles away at the Sri Aurobindo Institute of Medical Sciences in Indore, India. The operation, which involved a robotic atrial septal defect closure, was coordinated seamlessly by a team of local medical professionals in India and showcased the advanced capabilities of the SSi Mantra system, completing the surgery without technical issues and with minimal latency. This milestone not only highlights the potential for telesurgery to enhance access to complex cardiac care in underserved regions but also underscores SS Innovations’ commitment to making robotic surgery more affordable and accessible globally.
Potential Positives
- SS Innovations successfully completed the world's first intercontinental robotic cardiac telesurgery, showcasing the capabilities of its SSi Mantra 3 surgical robotic system.
- The surgical procedure was conducted remotely from over 4,000 miles away, demonstrating the company's innovative telesurgery technology and its potential to transform global healthcare delivery.
- The SSi Mantra 3 has been validated through the successful completion of 250 cardiac procedures, highlighting its reliability and effectiveness in complex surgical operations.
- SS Innovations is uniquely positioned as the only surgical robotic company to receive regulatory approval in India for both teleproctoring and telesurgery, enhancing its credibility and potential market reach.
Potential Negatives
- The press release emphasizes the unprecedented nature of the surgery, which might put significant pressure on the company to consistently deliver similar groundbreaking results in the future, raising expectations that could lead to scrutiny if future performances do not match this standard.
- Despite the success of the intercontinental robotic cardiac telesurgery, there is a lack of detailed information on the long-term outcomes for patients, which might raise concerns about the overall effectiveness and safety of the procedure.
- The focus on the company's advancements may overshadow the existing challenges in widespread adoption of such technology, including regulatory hurdles, training requirements for surgeons, and the potential costs for healthcare providers.
FAQ
What is the significance of the intercontinental robotic cardiac telesurgery?
The surgery marked the first successful remote cardiac procedure over 4,000 miles, showcasing advanced surgical robotic technology.
Who performed the robotic telesurgery?
The procedure was performed by Dr. Sudhir Srivastava, Chairman and CEO of SS Innovations, from IRCAD in France.
What technology was used in the telesurgery?
The surgery utilized the SSi Mantra 3 surgical robotic system, which features advanced telesurgery capabilities.
How many telesurgeries has SS Innovations conducted to date?
SS Innovations has successfully completed 35 telesurgeries, including 10 cardiac procedures, using the SSi Mantra system.
What distinguishes SS Innovations in the surgical robotics field?
SS Innovations is the only company with regulatory approval from CDSCO for both teleproctoring and telesurgery in India.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SSII Insider Trading Activity
$SSII insiders have traded $SSII stock on the open market 25 times in the past 6 months. Of those trades, 21 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $SSII stock by insiders over the last 6 months:
- SUDHIR SRIVASTAVA (Chairman and CEO) has made 0 purchases and 4 sales selling 6,170,734 shares for an estimated $8,466,247.
- FREDERIC H MOLL purchased 3,645,224 shares for an estimated $5,001,247
- TIMOTHY P. ADAMS purchased 1,250,000 shares for an estimated $1,715,000
- BARRY F COHEN (COO - Americas) has made 19 purchases buying 5,256 shares for an estimated $49,213 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Full Release
Performed by Dr. Sudhir Srivastava utilizing the Company’s SSi Mantra 3 surgical robotic system
Remotely conducted from IRCAD in Strasbourg, France, at an unprecedented distance of more than 4,000 miles to the operating room at SAIMS in Indore, India
FORT LAUDERDALE, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII) , a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that the Company’s Chairman of the Board and Chief Executive Officer, Dr. Sudhir Srivastava, M.D., successfully completed the world’s first intercontinental robotic cardiac telesurgery on July 19, 2025, utilizing the Company’s SSi Mantra 3 surgical robotic system.
Dr. Srivastava performed the cardiac procedure, a robotic atrial septal defect closure, remotely from the global headquarters of the Institute of Research Against Digestive Cancer (“IRCAD”) in Strasbourg, France, during the Society of Robotic Surgery (“SRS”) Annual Meeting at an unprecedented transmission distance of more than 4,000 miles to the operating room at the Sri Aurobindo Institute of Medical Sciences (“SAIMS”) in Indore, India.
Patient-side support in Indore was seamlessly coordinated by:
- Dr. Lalit Malik, Chief of Cardiac Surgery, Manipal Hospital, Jaipur;
- Dr. Ram Krishna Shukla, Cardiologist, SAIMS, Indore;
- Dr. Bipin Arya, Anesthesiologist, SAIMS, Indore; and
- the SS Innovations and SAIMS teams.
The live telesurgery was moderated by robotic cardiac surgeon Dr. Husam H. Balkhy, M.D., President of the International Society for Minimally Invasive Cardiothoracic Surgery (“ISMICS”) and Professor of Surgery and Director of Robotic and Minimally Invasive Cardiac Surgery at the University of Chicago Medicine.
Together, the team successfully completed the surgery without any technical issues and with an imperceptible latency, flawless precision, and seamless robotic control showcasing the robustness of the SSi Mantra 3 and its revolutionary telesurgery architecture.
Dr. Srivastava commented, “I would like to extend my gratitude to Dr. Vipul Patel, M.D., F.A.C.S., Chairman of the Society of Robotic Surgery for this opportunity at the SRS 2025 Conference, Dr. Mohit Bhandari, the IRCAD India team, and the entire SS Innovations team whose dedication and innovation made the world’s first intercontinental robotic cardiac telesurgery possible. This historic achievement not only demonstrates the advanced capabilities of our SSi Mantra 3 surgical robotic system but also further paves the way for redefining and democratizing global delivery of complex cardiac care, especially in regions with limited access to surgical expertise.”
The Company’s advanced SSi Mantra surgical robotic technology platform, including its cutting edge telesurgery capabilities, addresses traditional obstacles related to travel, time, cost, and surgical accessibility, creating a more efficient and equitable medical standard for both patients and surgeons.
To date, 35 telesurgeries including 10 cardiac procedures, and a total of 250 cardiac procedures have been successfully completed utilizing the SSi Mantra surgical robotic system. Cardiac-related procedures often rank among the most difficult operations to perform, which is testament to SSi Mantra’s capabilities in both telesurgery and complex soft-tissue surgeries in general. Additionally, over 5,000 multi-specialty surgeries have been successfully carried out with the SSi Mantra system without any device-related adverse events.
SS Innovations is the only surgical robotic company to have received a regulatory approval from the Central Drugs Standard Control Organization (“CDSCO”), which is India’s equivalent of the U.S. Food and Drug Administration, for both teleproctoring and telesurgery.
About SS Innovations
SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical procedures including robotic cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at
ssinnovations.com
or
LinkedIn
for more information and updates.
About the SSi Mantra
The SSi Mantra surgical robotic system is a user-friendly, modular, multi-arm system with many advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for all patient related information display, a virtual real-time image of the robotic patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery. The SSi Mantra has been clinically validated in India in more than 100 different types of surgical procedures.
Forward Looking Statements
This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SS Innovations’ future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.
Investor Contact:
The Equity Group
Kalle Ahl, CFA
T: (303) 953-9878
[email protected]
Devin Sullivan, Managing Director
T: (212) 836-9608
[email protected]
Media Contact:
RooneyPartners LLC
Kate Barrette
T: (212) 223-0561
[email protected]
